Goldman Sachs Group Inc Aquestive Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 114,009 shares of AQST stock, worth $620,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114,009
Previous 526,422
78.34%
Holding current value
$620,208
Previous $2.24 Million
86.8%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AQST
# of Institutions
102Shares Held
42.8MCall Options Held
271KPut Options Held
212K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$53.4 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$30.2 Million1.58% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$29.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$23 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.85MShares$15.5 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $290M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...